- IP Australia opens public consultation on proposed law changes
- Is India’s Expedited Examination Of Patents A Big Deal?
- Pharmaceutical Pricing Hostages
- DNDi welcomes Malaysia’s move to secure access to more affordable treatments for hepatitis C
- This Shield of Patents Protects the World’s Best-Selling Drug
Category Archives: Medicine Patent Pool
By Shreerupa Mitra-Jha, Firstpost | July 8, 2016 The UN-backed Medicines Patent Pool (MPP) announced on 7 July new generic manufacturing licensing, for antiretrovirals (ARVs) and direct acting anti-viral (DAA) for treating hepatitis C, with seven pharmaceutical companies, six of … Continue reading
GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries
Source: GSK Press Release, 31 March 2016 Adopts approach to intellectual property reflecting a country’s economic maturity Will not file for patent protection in Least Developed and Low Income Countries Will seek to grant licences to generic manufacturers to supply … Continue reading
The Medicines Patent Pool Signs a Collaborative Agreement with the University of Liverpool to Develop HIV Nanomedicines
Medicines Patent Pool; December 1, 2015. Geneva – The Medicines Patent Pool (MPP) today announced a collaboration with the University of Liverpool and a licence for the university’s Solid Drug Nanoparticle (SDN) technology to accelerate the development of WHO-recommended antiretrovirals as nanomedicines. The … Continue reading
Knowledge Ecology International, November 23, 2015. Knowledge Ecology International (KEI) notes the successful conclusion of negotiations between Bristol-Myers Squibb (BMS) and the Medicines Patent Pool (MPP) for a royalty-free license and technology transfer agreement on daclatasvir (DCV), an important new medicine … Continue reading
The Medicines Patent Pool Signs Licence with Bristol-Myers Squibb to Increase Access to Hepatitis C Medicine daclatasvir
PR Newswire; November 23, 2015. Geneva – The Medicines Patent Pool (MPP) today announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers Squibb for daclatasvir, a novel direct-acting antiviral that is proven to help cure multiple genotypes of … Continue reading
Medicines Patent Pool; November 6, 2015. Geneva – The Medicines Patent Pool (MPP), the world’s only voluntary licensing mechanism in public health, announced an expansion of its mandate today to hepatitis C and tuberculosis medicines.
Source: Aljazeera America Leak details intellectual property rights deal in Trans-Pacific Partnership under negotiation between US and 10 nations US President Barack Obama poses for a photograph with Trans-Pacific Partnership leaders. In its latest document dump, WikiLeaks unearthed what it … Continue reading